Curium’s $8B Lantheus Deal Forges a New Radiopharmaceutical Titan

BOSTON, MA – August 03, 2026 – In a move set to redefine the global nuclear medicine landscape, radiopharmaceutical leader Curium announced a definitive agreement today to acquire Lantheus Holdings for up to $8.0 billion. The strategic merger combines Curium’s formidable global manufacturing platform and theranostics pipeline with Lantheus’s powerhouse U.S. radiodiagnostics business, creating an integrated giant with unparalleled reach and capability.

The transaction, orchestrated by Curium’s controlling shareholder, private equity firm CapVest Partners, signals a bold consolidation in a sector experiencing explosive growth. By uniting two pioneers, the deal aims to create a comprehensive entity that can "Find, Fight, and Follow" disease—from initial diagnosis to targeted therapy—across oncology, neurology, and cardiology in over 70 countries.

The Financial Architecture of an $8 Billion Deal

For Lantheus shareholders, the deal presents a compelling mix of immediate certainty and future upside. Curium will acquire all outstanding Lantheus shares for $102.50 in cash at closing, providing a significant injection of near-term value. This cash portion alone represents a 21% premium over Lantheus's unaffected closing price on May 21, 2026, the last trading day before media reports of a potential sale first surfaced.

Layered on top of the upfront cash are non-transferable Contingent Value Rights (CVRs) that could add another $12.00 per share. These CVRs function as a performance-based incentive, with payouts tied to ambitious sales milestones for Lantheus's key product lines through 2030. The targets include its blockbuster prostate cancer diagnostics franchise (PYLARIFY), its growing neurology portfolio, and its established cardiac agent, DEFINITY. If all milestones are met, the total consideration would reach $114.50 per share, representing a hefty 38% premium to Lantheus’s unaffected 60-day volume-weighted average price.

While the CVRs offer a tantalizing prospect of additional returns, they come with inherent uncertainty, as there is no guarantee the sales targets will be achieved. However, the structure allowed Lantheus’s board to unanimously approve the transaction, which it deemed the "value maximizing path" after a comprehensive review of strategic alternatives that included outreach to multiple parties. "We believe this transaction is the ultimate validation of what the Lantheus team has built over seven decades of innovation," said Mary Anne Heino, Executive Chair and CEO of Lantheus.

The market had been buzzing with speculation for weeks, with Lantheus stock (NASDAQ: LNTH) already reflecting acquisition rumors. Upon the official announcement, the deal crystallizes the value that analysts and investors have increasingly seen in the company's market-leading diagnostics portfolio. Once the transaction closes, which is expected in the first half of 2027, Lantheus will cease to be a publicly traded company.

A Strategic Play for Market Dominance

At its core, this merger is a masterclass in strategic synergy. Curium, established by CapVest in 2017, has rapidly built a global empire in radiopharmaceuticals, with over 80 manufacturing sites and a presence in more than 70 countries. However, its U.S. footprint has been less developed. The acquisition of Lantheus provides an immediate, powerful solution to that gap.

Lantheus brings to the table a 70-year legacy in the U.S. market, highlighted by a robust commercial infrastructure and a portfolio of category-leading products. Its PYLARIFY imaging agent has been instrumental in establishing PSMA PET scans as the standard of care for prostate cancer. This, combined with its leadership in cardiac ultrasound with DEFINITY and its fast-growing neurology agent Neuraceq, gives Curium an enviable turnkey operation in the world’s largest healthcare market.

"Lantheus is the ideal partner to accelerate what we have been building at Curium," stated Renaud Dehareng, CEO of Curium Group. He emphasized that the combination "unlocks an opportunity that neither company could achieve alone."

The combined entity will be a true theranostics powerhouse. This term, referring to the integration of diagnostics and therapeutics, is the holy grail of modern nuclear medicine. The new company will control vast swathes of the value chain, from producing the essential radioactive isotopes to developing the diagnostic agents that find the disease and the radioligand therapies that fight it. This vertical integration is a powerful competitive moat in an industry where the short half-life of radioactive materials makes supply chain control paramount.

From Lab to Bedside: The Promise of Integrated Patient Care

Beyond the boardroom strategy and financial engineering, the merger holds significant promise for patients. By combining their respective strengths, the new entity is positioned to accelerate the development and broaden the accessibility of life-changing treatments. The integration of Curium’s therapeutic pipeline with Lantheus’s diagnostic expertise could streamline the creation of "theranostic pairs"—linked diagnostic and therapeutic agents that target the same cellular marker, enabling a more precise and personalized approach to medicine.

For patients, this could mean a more seamless journey from diagnosis to treatment. A single, integrated company is better equipped to overcome the logistical hurdles that have historically plagued the radiopharmaceutical industry. With a combined global manufacturing network and deep expertise in handling time-sensitive radioactive materials, the new Curium could mitigate the supply chain bottlenecks that can delay critical scans and therapies.

Furthermore, the deal promises to expand global access to proven diagnostics. Lantheus’s successful U.S. products like PYLARIFY and Neuraceq can now leverage Curium’s extensive international distribution network, potentially making these advanced imaging agents available to millions more patients worldwide. Conversely, Curium's therapeutic innovations will have a clear and established path into the U.S. market through Lantheus’s commercial channels, speeding their availability to American patients.

The CapVest Blueprint and the Regulatory Path Forward

This transaction is the latest and most ambitious move in CapVest's long-term strategy to build a dominant force in nuclear medicine. The private equity firm, which remains Curium's controlling shareholder, has shown a deep conviction in the sector's potential. Just last year, it completed a successful recapitalization of Curium in a transaction that valued the group at approximately $7 billion, demonstrating strong investor confidence.

Kate Briant, Senior Partner at CapVest and Chair of Curium’s Board, framed the acquisition as a commitment to growth and a belief in the future of the sector. "This highly strategic combination will allow the combined company to capitalize on the significant emerging opportunities and, most importantly, will allow us to accelerate bringing life-changing solutions to healthcare professionals," she said. CapVest’s strategy reflects a classic private equity playbook: identify a resilient, high-growth industry, consolidate key players to build scale, and create an integrated business that controls its own destiny.

Before this vision can be fully realized, however, the deal must navigate a rigorous regulatory review process. Given the transaction's size and the significant market share of the combined entity, it will undoubtedly face close scrutiny from antitrust authorities like the Federal Trade Commission (FTC) in the U.S. and equivalent bodies in other jurisdictions. Regulators will be looking closely at how the merger could affect competition, pricing, and the pace of innovation in the radiopharmaceutical market. The projected closing in the first half of 2027 suggests both companies are prepared for a thorough, if lengthy, approval process.

The successful completion of this merger will not only create a new titan in the industry but also serve as a powerful testament to the central role that radiopharmaceuticals are poised to play in the future of medicine.